Blinatumomab (Blincyto®) for the treatment of paediatric patients (aged 1 year plus) with high-risk first-relapsed Ph- CD19+ B-precursor acute lymphoblastic leukaemia as part of consolidation therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||05/07/2021|
|Rapid review completed||03/08/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that blinatumomab not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.